基于结构设计的强大和选择性的YTHDC1连接体
František Zálešák1, Francesco Nai1, Marcin Herok1
1Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
Journal of medicinal chemistry
|May 24, 2024
概括
研究人员开发了一种新型的抑制剂,化合物40,向YTHDC1,这是N6-氨酸甲基化 (m6A) RNA修饰中的关键蛋白质. 这种化合物对急性髓性白血病细胞具有显著的抗增殖作用,作为进一步研究的宝贵工具.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- N6-氨酸甲基化 (m6A) 是一个关键的mRNA修饰调节基因表达.
- YTHDC1是核读取蛋白,专门识别m6A的修改.
研究的目的:
- 使用基于结构的药物化学方法设计和合成YTHDC1的新型抑制剂.
- 在急性髓性白血病 (AML) 的背景下,评估开发的抑制剂,特别是化合物40的生物化学和细胞活性.
主要方法:
- 基于蛋白质结构的药物设计和药物化学运动.
- 生物化学测试以确定抑制剂亲和力 (Kd) 和对m6A读数的选择性.
- 细胞测定包括抗增殖活性和细胞热转移测定 (CETSA) 用于目标参与.
主要成果:
- 化合物40被确定为一种强大的YTHDC1抑制剂,Kd为49nM.
- 以1.6 Å分辨率的晶体结构证实了结合模式并验证了设计.
- 化合物40对细胞质YTHDF1-3和YTHDC2阅读器具有选择性.
- 对AML细胞系 (THP-1,MOLM-13,NOMO-1) 观察到显著的抗增殖活性.
- 生物化学亲和力和细胞抗增殖活性之间的相关性证实了YTHDC1在细胞中的向参与.
结论:
- 化合物40是一种选择性和强大的YTHDC1抑制剂,在AML细胞中具有已证明的抗增殖作用.
- 这项研究提供了强有力的证据,证明YTHDC1在AML中的作用.
- 化合物40作为一种有价值的化学探针,用于调查YTHDC1在AML病变发生过程中的功能.
相关概念视频
02:40Ligand Binding Sites
12.8K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.8K
01:28Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
01:25Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K